Variability in Adrenergic Response
Information source: Vanderbilt University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Vascular Reaction to Medications
Intervention: phenylephrine and nitroglycerin (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Vanderbilt University Official(s) and/or principal investigator(s): Charles M Stein, MD, Principal Investigator, Affiliation: Vanderbilt University
Summary
The goal of this project is to determine the genetic factors contributing to interindividual
differences in response to physiological and pharmacological vasoconstrictors and
vasodilators.
Clinical Details
Official title: Variability in Adrenergic Response
Study design: Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label
Primary outcome: sensitivity to phenylephrine and nitroglycerin
Secondary outcome: cardiovascular responses to cold and mental stress
Detailed description:
The dorsal hand vein model is a relatively non-invasive and robust experimental model to
examine the local in vivo effect of vasoactive drugs without elucidating systemic
counterregulatory reflexes. Infusion of incremental low doses of phenylephrine into a dorsal
hand vein results in increasing local venoconstriction, without systemic effects. Similarly,
infusion of incremental low doses of nitroglycerin into a preconstricted dorsal hand vein
results in increasing local venodilation, without systemic effects. Systemic vascular
responses can be measured by the cold pressor test (CPT),that leads to increase in blood
pressure and heart rate , or mental stress that is also known to stimulate cardiovascular
responses. Individuals vary in their local and systemic vascular responses but the genetic
determinants of these are not clear.
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age between 18 and 40 years, inclusive.
- Subject must be willing to give written informed consent and be able to adhere to
diet and study schedules.
- Subjects must be free of any clinically significant disease that requires a
physician's care and/or would interfere with the study evaluations.
- Subjects must have a normal or clinically acceptable physical examination and ECG.
- Clinical laboratory tests (CBC, blood chemistries, and urinalysis) must be within
normal limits or clinically acceptable to the investigator.
Exclusion Criteria:
- Any subject who has taken any prescription or over-the-counter drugs, other than oral
contraception if female, within two weeks prior to study drug administration.
- Subjects who are presently, or were formerly, narcotic addicts or alcoholics.
- Subjects who have a clinically significant allergy/intolerance to phenylephrine.
- Females with a positive serum/urine pregnancy test at screening.
- Females who are nursing.
- Subject using sildenafil or other phosphodiesterase inhibitors.
Locations and Contacts
Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
Additional Information
Starting date: January 2009
Last updated: June 16, 2015
|